What is Dash Bio?
Dash Bio operates at the intersection of biotechnology and high-throughput automation, positioning itself as a critical infrastructure provider for the biopharma industry. By integrating robotics, AI-driven data processing, and GLP-compliant software, the company effectively removes the bottlenecks inherent in traditional clinical trial timelines. Its platform is engineered to deliver high-fidelity bioanalytical results with unprecedented speed, enabling pharmaceutical teams to accelerate the transition of life-saving therapies from the laboratory to the patient. As the industry faces increasing pressure to reduce drug development costs, Dash Bio's automated lab-as-a-service model provides a scalable solution for complex analytical requirements.
How much funding has Dash Bio raised?
Dash Bio has raised a total of $47.5M across 3 funding rounds:
Angel/Seed
$6.5M
Unspecified
$11M
Stock/Share Issuance
$30M
Angel/Seed (2024): $6.5M with participation from Freestyle, LifeX Labs, and Swift Ventures
Unspecified (2025): $11M led by LifeX Ventures, Cybernetix Ventures, Freestyle Capital, and Swift Ventures
Stock/Share Issuance (2026): $30M, investors not publicly disclosed
Key Investors in Dash Bio
LifeX Ventures
A venture firm dedicated to life extension and health innovation, supporting startups that utilize AI and scientific breakthroughs to improve human longevity.
Cybernetix Ventures
A specialized VC firm focusing on robotics, automation, and AI, with a strong emphasis on enhancing operational efficiency within the healthcare and manufacturing sectors.
Freestyle Capital
An early-stage venture capital firm known for its founder-centric approach and strategic support of high-growth technology companies during their initial development phases.
What's next for Dash Bio?
The recent capital injection is expected to catalyze Dash Bio's expansion into broader therapeutic markets and enhance its existing AI-driven analytical capabilities. By leveraging this strategic investment, the company is well-positioned to deepen its operational footprint, potentially increasing its throughput capacity to meet the growing demand for rapid clinical data. Future growth will likely focus on strengthening its technological moat through further R&D in automated diagnostics and expanding its partnerships with global biopharma entities, ensuring that Dash Bio remains at the forefront of the digital transformation in life sciences.
See full Dash Bio company page
